Organization
Department of Theranostics and Nuclear Medicine
2 abstracts
Abstract
Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).Org: Department of Theranostics and Nuclear Medicine, Cancer Imaging, Prostate Cancer Theranostics and Imaging Centre of Excellence, Perth, Western Australia, Australia, ANZUP Cancer Clinical Trials Group,
Abstract
64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.Org: Clarity Pharmaceuticals, Eveleigh, Nepean Hospital, GenesisCare, Fort Myers, FL, Department of Theranostics and Nuclear Medicine,